Literature DB >> 7845018

Expression of the Evi-1 gene in myelodysplastic syndromes.

F Dreyfus1, D Bouscary, J Melle, V Ribrag, M Guesnu, B Varet.   

Abstract

Increased expression of the proto-oncogene Evi-1 has been shown to block the in vitro granulocytic differentiation of myeloid cells in response to granulocytic colony-stimulating factor and to interfere with the proliferation of erythroid cells in response to erythropoietin. We determined the frequency of Evi-1 expression in myelodysplastic syndromes (MDS), a disorder with altered proliferation and differentiation in the erythroid and myeloid lineages. Twenty-one patients were studied. Abnormal expression was found in 1/9 patients with refractory anemia and in 7/12 patients with refractory anemia with excess of blasts (RAEB) or in transformation (RAEBt). No correlation could be found between expression of Evi-1 and age, sex, hemoglobin level and percentage of bone marrow blasts or erythroblasts. This result suggests that the high incidence of Evi-1 expression which remains at low levels in RAEB and RAEBt is not a major determinant of ineffective erythropoiesis and myelopoiesis in MDS.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7845018

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  7 in total

1.  Overexpression of EVI1 interferes with cytokinesis and leads to accumulation of cells with supernumerary centrosomes in G0/1 phase.

Authors:  Kadin Karakaya; Friederike Herbst; Claudia Ball; Hanno Glimm; Alwin Krämer; Harald Löffler
Journal:  Cell Cycle       Date:  2012-08-16       Impact factor: 4.534

2.  Myeloid leukemia with high EVI1 expression is sensitive to 5-aza-2'-deoxycytidine by targeting miR-9.

Authors:  F Li; W He; R Geng; X Xie
Journal:  Clin Transl Oncol       Date:  2019-05-03       Impact factor: 3.405

3.  Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease.

Authors:  Stefan Stein; Marion G Ott; Stephan Schultze-Strasser; Anna Jauch; Barbara Burwinkel; Andrea Kinner; Manfred Schmidt; Alwin Krämer; Joachim Schwäble; Hanno Glimm; Ulrike Koehl; Carolin Preiss; Claudia Ball; Hans Martin; Gudrun Göhring; Kerstin Schwarzwaelder; Wolf-Karsten Hofmann; Kadin Karakaya; Sandrine Tchatchou; Rongxi Yang; Petra Reinecke; Klaus Kühlcke; Brigitte Schlegelberger; Adrian J Thrasher; Dieter Hoelzer; Reinhard Seger; Christof von Kalle; Manuel Grez
Journal:  Nat Med       Date:  2010-01-24       Impact factor: 53.440

4.  Acetylation of the proto-oncogene EVI1 abrogates Bcl-xL promoter binding and induces apoptosis.

Authors:  Anjan Kumar Pradhan; Alok Das Mohapatra; Kasturi Bala Nayak; Soumen Chakraborty
Journal:  PLoS One       Date:  2011-09-28       Impact factor: 3.240

5.  EVI1 promotes tumor growth via transcriptional repression of MS4A3.

Authors:  Gerwin Heller; Anna Rommer; Katarina Steinleitner; Julia Etzler; Hubert Hackl; Petra Heffeter; Erwin Tomasich; Martin Filipits; Birgit Steinmetz; Thais Topakian; Simone Klingenbrunner; Barbara Ziegler; Andreas Spittler; Sabine Zöchbauer-Müller; Walter Berger; Rotraud Wieser
Journal:  J Hematol Oncol       Date:  2015-03-21       Impact factor: 17.388

6.  Inducible expression of EVI1 in human myeloid cells causes phenotypes consistent with its role in myelodysplastic syndromes.

Authors:  Torsten A Konrad; Anna Karger; Hubert Hackl; Ilse Schwarzinger; Irene Herbacek; Rotraud Wieser
Journal:  J Leukoc Biol       Date:  2009-07-15       Impact factor: 4.962

7.  The oncogene EVI1 enhances transcriptional and biological responses of human myeloid cells to all-trans retinoic acid.

Authors:  Birgit Steinmetz; Hubert Hackl; Eva Slabáková; Ilse Schwarzinger; Monika Smějová; Andreas Spittler; Itziar Arbesu; Medhat Shehata; Karel Souček; Rotraud Wieser
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.